These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1124 related articles for article (PubMed ID: 31616440)

  • 1. NK Cell Metabolism and Tumor Microenvironment.
    Terrén I; Orrantia A; Vitallé J; Zenarruzabeitia O; Borrego F
    Front Immunol; 2019; 10():2278. PubMed ID: 31616440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment.
    Moinuddin A; Poznanski SM; Portillo AL; Monteiro JK; Ashkar AA
    Immunol Rev; 2024 May; 323(1):19-39. PubMed ID: 38459782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and metabolic targeting of natural killer cells to solid tumors.
    Wang J; Matosevic S
    Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
    Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
    J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
    Lian G; Mak TS; Yu X; Lan HY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
    Zalfa C; Paust S
    Front Immunol; 2021; 12():633205. PubMed ID: 34025641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
    Nachef M; Ali AK; Almutairi SM; Lee SH
    Front Immunol; 2021; 12():624324. PubMed ID: 33953707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
    Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
    JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.
    Bödder J; Zahan T; van Slooten R; Schreibelt G; de Vries IJM; Flórez-Grau G
    Front Immunol; 2020; 11():631713. PubMed ID: 33679726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function.
    Rossi GR; Trindade ES; Souza-Fonseca-Guimaraes F
    Front Immunol; 2020; 11():73. PubMed ID: 32063906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of tumor cells escaping from immune surveillance of NK cells.
    Ge Z; Wu S; Zhang Z; Ding S
    Immunopharmacol Immunotoxicol; 2020 Jun; 42(3):187-198. PubMed ID: 32223464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.
    Murray S; Lundqvist A
    Hum Vaccin Immunother; 2016 Mar; 12(3):607-11. PubMed ID: 26402368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
    Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
    Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.
    Bald T; Krummel MF; Smyth MJ; Barry KC
    Nat Immunol; 2020 Aug; 21(8):835-847. PubMed ID: 32690952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells: An attractive candidate for cancer therapy.
    Valipour B; Velaei K; Abedelahi A; Karimipour M; Darabi M; Charoudeh HN
    J Cell Physiol; 2019 Nov; 234(11):19352-19365. PubMed ID: 30993712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy.
    Devillier R; Chrétien AS; Pagliardini T; Salem N; Blaise D; Olive D
    J Leukoc Biol; 2021 Jun; 109(6):1071-1088. PubMed ID: 32991746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.